Sunshine Heart Inc news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

SSH 4.33 -0.03 (-0.69%)
price chart
Canaccord Reiterates Buy on Sunshine Heart Inc Following FDA Review of IDE ...
Canaccord's healthcare analyst Jason Mills weighed in with an optimistic view on Sunshine Heart Inc (NASDAQ:SSH), following the news that the FDA responded to the company's IDE supplement.
Form 8-K Sunshine Heart, Inc. For: Apr 16
Sunshine Heart Provides Update on US Pivotal Study of C-Pulse(R) Heart ...  MarketWatch
Form 8-K Sunshine Heart, Inc. For: Apr 20
On April 20, 2015, Sunshine Heart, Inc. (the �Company�) entered into a Second Amendment (the �Amendment�) to the Company's lease (the �Lease�) with Capital Partners Industrial Fund I, LLLP dba Prairie Crossroads Business Center (the �Landlord�) ...
Sunshine Heart's new device is heartening news
Sunshine Heart Inc. is creating plenty of buzz with a new heart assist device that could reverse heart damage in some patients.
Related articles »  
Canaccord Pounds the Table on Sunshine Heart Inc
Canaccord Genuity analyst Jason Mills was out pounding the table on Sunshine Heart Inc (NASDAQ:SSH) Thursday, reiterating a Buy rating and a $7.50 price target, which represents a potential upside of 82.5% from where the stock is currently trading.
Sunshine Heart Receives a Buy from Cowen & Co.  Analyst Ratings
Sunshine Heart, Inc. Secures Up to $10 Million in Growth Capital From Silicon ...
19, 2015 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq:SSH) (the "Company" or "Sunshine Heart") today announced that it has entered into a loan and security agreement with Silicon Valley Bank to provide up to $10.0 million in growth capital.
Here's Why Sunshine Heart Inc (SSH) Stock is Trending Up By 18% Today
Sunshine Heart Inc (NASDAQ:SSH) has received an unrestricted approval for holding a provisional analysis of the COUNTER HF study from the US Food and Drug Administration (FDA), the company announced on Wednesday.
Canaccord Praises Sunshine Heart (SSH) Following FDA Approval For Interim ...  Smarter Analyst
Sunshine Heart Receives FDA Approval for Interim Analysis of U.S. Pivotal ...  GlobeNewswire (press release)
Sunshine Heart (SSH) Stock Drops Today After Suspending Study Enrollment
"We rate SUNSHINE HEART INC (SSH) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of ...
Sunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse(R) Heart ...  GlobeNewswire (press release)
Sunshine Heart Inc.: A Sleeping Giant [Thoratec Corporation, HeartWare ...
Sunshine Heart (NASDAQ:SSH) is developing a medical device that could revolutionize how Class III/IV Congestive Heart Failure (CHF) patients are treated. The medical device is called C-Pulse, and was invented by the co-founder of the company, Dr.
Sunshine Heart Inc (SSH) news: Sunshine Heart: Unexpected Buying Opportunity
I am encouraged by what Dave Rosa, CEO of Sunshine Heart, had to say in the 4th quarter conference call about actions taken and being taken to accelerate enrollments.
Related articles »  
Healthcare Stocks Seeking Failure - Sunshine Heart Inc (NASDAQ:SSH), Geron ...
Sunshine Heart Inc. (SSH), declared an update on COUNTER HF(TM), the Corporation's U.S. pivotal study which is a prospective, randomized, multi-center, controlled study evaluating the safety and efficacy of the C-Pulse system for the treatment of NYHA ...